Daniell Richard, Executive VP of European Commercial operations, has demonstrated a clear selling bias in their trading activity involving Teva Pharmaceutical Industries (TEVA), the sole company represented in their SEC Form 4 filings. Over 45 reported transactions, Richard has sold $17.57 million worth of TEVA shares while purchasing just $2.12 million, resulting in a net divestment of approximately $15.42 million. The selling activity has intensified recently, with 13 disposals recorded since December 2025, including multiple high-value transactions in March 2026. On March 3-4, 2026 alone, Richard sold over $6.5 million in TEVA stock across five separate transactions, with individual sales ranging from $664,256 to $2.16 million.
The pattern shows consistent disposals punctuated by occasional smaller purchases, with the most recent buy occurring over a year prior. Notably, Richard's March 2026 sales followed a similar pattern to their March 2025 activity, when they disposed of $2.69 million in TEVA shares across seven transactions. The largest single sale occurred on December 9, 2025, when Richard sold $3.31 million worth of stock alongside $2.12 million in derivative transactions coded as "M" (likely option exercises). This sustained selling trend, particularly the concentration of disposals in early March across multiple years, suggests a systematic approach to reducing TEVA exposure rather than isolated portfolio rebalancing.
AI-assisted summary